+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hepatic arterial chemotherapy in combination with systemic chemotherapy compared with hepatic arterial chemotherapy alone for liver metastases from colorectal cancer: results of a multi-centric randomized study



Hepatic arterial chemotherapy in combination with systemic chemotherapy compared with hepatic arterial chemotherapy alone for liver metastases from colorectal cancer: results of a multi-centric randomized study



In Vivo 20(6a): 707-709



Hepatic arterial infusion (HAI) chemotherapy is accepted to be an option in patients with non-resectable metastases from colorectal cancer confined to the liver. In a multi-istitutional trial, 76 patients were randomly assigned to receive HAI versus HAI plus systemic bolus 5-fluorouracil and leucovorin. The primary endpoint was survival, followed by response, recurrence and toxicity. Survival was longer for HAI plus systemic chemotherapy (HAI+SYC) than HAI (median, 20 vs. 14 months; p = 0.0033), as were responses (47.5% and 41.7%; p = 0.09) and time to hepatic progression (12 vs. 8 months; p = 0.039). Side effects included haematological toxicity that was mostly mild and reversible in 432 cases. Neutropenia grade 3 occurred in four patients in the HAI+SYC arm and one in the HAI arm. Diarrhoea occurred in 20% and 7% of patients and stomatitis occurred in 18% and 2%, respectively. On the contrary biliary toxicity was significant; twelve patients had evidence of bilirubin elevations of more than 3 mg/dl (six in each arm), and two had asymptomatic arterial biliary-tree fistulae: one in the HAI+SYC arm and one in the HAI arm. Grade 3 elevation in alkaline phosphatase and aminotransferase levels occurred in 26% and 24%, respectively. In conclusion, the combination of HAI+SYC is active and safe showing a clinical advantage with respect to simple HAI, increasing overall survival, response rate and time to progression.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 049209060

Download citation: RISBibTeXText

PMID: 17203750


Related references

Hepatic arterial chemotherapy in combination with systemic chemotherapy compared with hepatic arterial chemotherapy alone for liver metastases from colorectal cancer: Results of a multi-centric randomized study. In Vivo (Attiki) 20(6A): 707-709, 2006

A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundation for Multidisciplinary Treatment of Cancer 32). Journal of Cancer Research and Therapeutics 14(Suppl.): S761-S766, 2018

Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case-Control Study. Annals of Surgical Oncology 24(1): 150-158, 2016

Hepatic arterial infusion chemotherapy with oxaliplatin in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(12): 2594-2597, 2011

Clinical results of pharmacokinetic modulating chemotherapy (PMC) in combination with hepatic arterial 5FU infusion, continuous venous 5FU infusion and oral UFT as adjuvant chemotherapy after liver resection for hepatic colorectal metastases. Journal of Clinical Oncology 23(16_Suppl): 3665-3665, 2016

Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: a phase II trial using intermittent percutaneous hepatic arterial access. Journal of Clinical Oncology 19(9): 2404-2412, 2001

Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. Annals of Surgery 257(1): 114-120, 2013

Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(13): 2033-2037, 2007

Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. Journal of Clinical Oncology 23(22): 4888-4896, 2005

Systemic or hepatic arterial chemotherapy after curative resection of liver metastases from colorectal cancer. A meta-analysis of randomized controlled trials. Journal of Clinical Oncology 26(15_Suppl): 4077-4077, 2016

Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. Journal of Clinical Oncology 29(7): 884-889, 2011

Hepatic arterial infusion chemotherapy prior to standard systemic chemotherapy in patients with highly advanced unresectable liver metastases from colorectal cancer: a report of three patients. Acta Medica Okayama 65(1): 49-53, 2011

Loco-regional chemotherapy of hepatic metastases of colorectal origin: failure of arterial chemotherapy; value of portal chemotherapy associated with ligation of the hepatic artery. Gastroenterologie Clinique et Biologique 8(6-7): 577, 1984

Two Cases of Effective Hepatic Arterial Infusion Chemotherapy for Liver Metastases of Colon Cancer Resistant to Systemic Chemotherapy. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(12): 1518-1520, 2016

A case of successfully treated unresectable multiple liver metastases from colon cancer by hepatic arterial infusion chemotherapy and systemic chemotherapy. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(12): 1953-1955, 2007